Exome-First Strategy in Adult Patients With CKD : A Cohort Study
© 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology..
Introduction: Exome sequencing (ES) has widened the field of nephrogenomics in adult nephrology. In addition to reporting the diagnostic yield of ES in an adult cohort study, we investigated the clinical implications of molecular diagnosis and developed a clinical score to predict the probability of obtaining positive result.
Methods: From September 2018 we have used ES to prospectively perform a first-tier liberal exploration of adult nephropathies of unknown origin and/or when a genetic kidney disease was clinically suggested. We also analyzed copy number variant using the same assay.
Results: Molecular diagnosis was made in 127 of 538 patients sequenced (diagnostic yield: 24%), comprising 47 distinct monogenic disorders. Eight of these monogenic disorders (17% [8/47]) accounted for 52% of genetic diagnoses. In 98% (n = 125/127) of the patients, the genetic information was reported to have major clinical implications. We developed a 4-value clinical score to predict the probability of obtaining a molecular diagnosis (area under the receiver operating characteristics curve [AUC] 0.726 [95% confidence interval: 0.670-0.782]) (available at http://allogenomics.com/score).
Conclusion: This study reinforces the role of ES as a first-tier exploration for adult chronic kidney disease patients in whom phenotypes are often poor and atypical. Although external validation is required, our clinical score could be a useful tool for the implementation of nephrogenomics in adults.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Kidney international reports - 8(2023), 3 vom: 01. März, Seite 596-605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doreille, Alice [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CKD of unknown origin |
|---|
| Anmerkungen: |
Date Revised 21.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2022.12.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354434799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354434799 | ||
| 003 | DE-627 | ||
| 005 | 20231226062220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2022.12.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354434799 | ||
| 035 | |a (NLM)36938085 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doreille, Alice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exome-First Strategy in Adult Patients With CKD |b A Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology. | ||
| 520 | |a Introduction: Exome sequencing (ES) has widened the field of nephrogenomics in adult nephrology. In addition to reporting the diagnostic yield of ES in an adult cohort study, we investigated the clinical implications of molecular diagnosis and developed a clinical score to predict the probability of obtaining positive result | ||
| 520 | |a Methods: From September 2018 we have used ES to prospectively perform a first-tier liberal exploration of adult nephropathies of unknown origin and/or when a genetic kidney disease was clinically suggested. We also analyzed copy number variant using the same assay | ||
| 520 | |a Results: Molecular diagnosis was made in 127 of 538 patients sequenced (diagnostic yield: 24%), comprising 47 distinct monogenic disorders. Eight of these monogenic disorders (17% [8/47]) accounted for 52% of genetic diagnoses. In 98% (n = 125/127) of the patients, the genetic information was reported to have major clinical implications. We developed a 4-value clinical score to predict the probability of obtaining a molecular diagnosis (area under the receiver operating characteristics curve [AUC] 0.726 [95% confidence interval: 0.670-0.782]) (available at http://allogenomics.com/score) | ||
| 520 | |a Conclusion: This study reinforces the role of ES as a first-tier exploration for adult chronic kidney disease patients in whom phenotypes are often poor and atypical. Although external validation is required, our clinical score could be a useful tool for the implementation of nephrogenomics in adults | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CKD of unknown origin | |
| 650 | 4 | |a exome sequencing | |
| 650 | 4 | |a nephrogenomics | |
| 700 | 1 | |a Lombardi, Yannis |e verfasserin |4 aut | |
| 700 | 1 | |a Dancer, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Lamri, Radoslava |e verfasserin |4 aut | |
| 700 | 1 | |a Testard, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Vanhoye, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Lebre, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Rafat, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Ouali, Nacera |e verfasserin |4 aut | |
| 700 | 1 | |a Luque, Yosu |e verfasserin |4 aut | |
| 700 | 1 | |a Izzedine, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Esteve, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Cez, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Petit-Hoang, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a François, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Marchal, Armance |e verfasserin |4 aut | |
| 700 | 1 | |a Letavernier, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Frémeaux-Bacchi, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Boffa, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Rondeau, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Raymond, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Mesnard, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 8(2023), 3 vom: 01. März, Seite 596-605 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:596-605 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2022.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 3 |b 01 |c 03 |h 596-605 | ||